Canada markets close in 3 hours 42 minutes
  • S&P/TSX

    20,651.47
    +55.58 (+0.27%)
     
  • S&P 500

    4,372.85
    +22.92 (+0.53%)
     
  • DOW

    34,458.71
    +290.62 (+0.85%)
     
  • CAD/USD

    0.7863
    -0.0033 (-0.42%)
     
  • CRUDE OIL

    87.23
    -0.12 (-0.14%)
     
  • BTC-CAD

    46,288.67
    -2,717.73 (-5.55%)
     
  • CMC Crypto 200

    833.01
    +13.51 (+1.65%)
     
  • GOLD FUTURES

    1,793.40
    -36.30 (-1.98%)
     
  • RUSSELL 2000

    1,970.48
    -5.99 (-0.30%)
     
  • 10-Yr Bond

    1.8030
    -0.0450 (-2.44%)
     
  • NASDAQ

    13,537.26
    -4.86 (-0.04%)
     
  • VOLATILITY

    30.17
    -1.79 (-5.60%)
     
  • FTSE

    7,554.31
    +84.53 (+1.13%)
     
  • NIKKEI 225

    26,170.30
    -841.03 (-3.11%)
     
  • CAD/EUR

    0.7053
    +0.0033 (+0.47%)
     

Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • TBGNF

Negma Group has converted 200 convertible bonds in Oxurion resulting in a EUR 500,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidates that are targeting potential market opportunities of over USD 12 billion.

Leuven, BE, Boston, MA, US – November 30, 2021 – 07.00 AM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of 263,157 new ordinary shares on November 10 (as listed on November 15), 2021, for a total amount of EUR 500,000 (including an issue premium amounting to EUR 121,503.92), as the result of the conversion of 200 convertible bonds pursuant to the Capital Commitment entered into with Negma Group.

Following completion of the capital increase, the total number of shares issued by Oxurion amounts to 38,863,796 outstanding ordinary shares carrying voting rights (compared to 38,600,639 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.

Therefore, Oxurion publishes the following updated information:

56,149,419.24

38,863,796

38,863,796

END

For further information please contact:

Oxurion NV



Tom Graney
Chief Executive Officer
Tel: +32 16 75 13 10
tom.graney@oxurion.com



Michaël Dillen
Chief Business Officer
Tel: +32 479 783 583
michael.dillen@oxurion.com

EU
MEDiSTRAVA Consulting
David Dible/Sylvie Berrebi/Frazer Hall
Tel: +44 20 7638 9571
oxurion@medistrava.com



US
Westwicke, an ICR company
Christopher Brinzey
Tel: +1 617 835 9304
chris.brinzey@westwicke.com

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide as well as other conditions, including wet age-related macular degeneration (wet AMD) and retinal vein occlusion (RVO).

Oxurion is aiming to build a leading global franchise in the treatment of retinal vascular disorders based on the successful development of its two novel therapeutics:

  • THR-687 is a highly selective pan-RGD integrin antagonist that is initially being developed as a potential first line therapy for DME patients. Positive topline results in a Phase 1 clinical study assessing THR-687 as a treatment for DME were announced in 2020. Oxurion is currently conducting a Phase 2 clinical trial (“INTEGRAL”) evaluating THR-687 in patients with DME. THR-687 also has the potential to deliver improved treatment outcomes for patients with wet AMD and RVO.

  • THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the 40-50% of DME patients showing suboptimal response to anti-VEGF therapy. THR-149 has shown positive topline Phase 1 results for the treatment of DME. The Company is currently conducting a Phase 2 clinical trial (“KALAHARI”) evaluating multiple injections of THR-149 in DME patients previously showing a suboptimal response to anti-VEGF therapy. Following positive data from Part A of this Phase 2 study (dose selection), the Company has initiated Part B of the study.

Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

1 Press release Oxurion, 06/04/2021


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting